SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
NEWARK, N.Y., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ:ULBI) has acquired all of the outstanding shares of Accutronics Ltd., for £7.575 million (approximately $11.0 million) in cash, subject to customary working capital and net cash/debt adjustments. Based in Newcastle-under-Lyme, U.K., Accutronics Ltd. is a leading independent designer and manufacturer of smart batteries and charger systems for high-performance, feature-laden portable and handheld electronic devices.
With a portfolio encompassing custom battery design, development and manufacturing for OEM’s; standard smart batteries, chargers and accessories; and pre-engineered batteries and power solutions for specific applications, Accutronics primarily serves the portable medical device market throughout Europe. Medical applications include digital imaging, ventilators, anaesthesia, endoscopy, patient monitoring, cardio pulmonary care, oxygen concentration and aspiration. For their fiscal year ended August 31, 2015, Accutronics generated revenue of over £8 million (approximately $12.5 million). The transaction is expected to be accretive on an EPS basis within 12 months.
“To further drive the proven operating leverage of our business model, we are focused on revenue growth from new product development and market and sales reach expansion, while seeking acquisitions that enhance our organic growth opportunities. Accutronics, a well-run, profitable company with a compatible business model, growth profile and management approach, is a great bolt-on fit to our Battery and Energy Products business unit,” said Michael D. Popielec, Ultralife's President and Chief Executive Officer. “Acquiring Accutronics advances our strategy of commercial revenue diversification and expands our geographic reach within European OEM’s. With industry experts predicting mid-to-high single digit growth in the global medical batteries market, this strategic investment positions Ultralife well for further penetration of and growing revenue streams from an attractive commercial market.”
About Ultralife Corporation
Ultralife Corporation serves its markets with products and services ranging from portable power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government, defense and commercial customers across the globe.
Headquartered in Newark, New York, the Company's business segments include: Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorp.com.
This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include: potential reductions in U.S. military spending, uncertain global economic conditions and acceptance of our new products on a global basis. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.
Company Contact: Ultralife Corporation Philip A. Fain (315) 332-7100 [email protected] Investor Relations Contact: LHA Jody Burfening (212) 838-3777 [email protected]
